- Home
- BOLD vs VRCA Comparison
BOLD vs VRCA Comparison
Compare BOLD & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLD
- VRCA
- Stock Information
- Founded
- BOLD 2018
- VRCA 2013
- Country
- BOLD United States
- VRCA United States
- Employees
- BOLD N/A
- VRCA N/A
- Industry
- BOLD
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- BOLD
- VRCA Health Care
- Exchange
- BOLD Nasdaq
- VRCA Nasdaq
- Market Cap
- BOLD 30.3M
- VRCA 43.0M
- IPO Year
- BOLD 2024
- VRCA 2018
- Fundamental
- Price
- BOLD $1.50
- VRCA $0.42
- Analyst Decision
- BOLD Hold
- VRCA Hold
- Analyst Count
- BOLD 1
- VRCA 5
- Target Price
- BOLD N/A
- VRCA $6.00
- AVG Volume (30 Days)
- BOLD 63.1K
- VRCA 243.3K
- Earning Date
- BOLD 05-16-2025
- VRCA 05-13-2025
- Dividend Yield
- BOLD N/A
- VRCA N/A
- EPS Growth
- BOLD N/A
- VRCA N/A
- EPS
- BOLD N/A
- VRCA N/A
- Revenue
- BOLD N/A
- VRCA $7,566,000.00
- Revenue This Year
- BOLD N/A
- VRCA $127.58
- Revenue Next Year
- BOLD N/A
- VRCA $88.06
- P/E Ratio
- BOLD N/A
- VRCA N/A
- Revenue Growth
- BOLD N/A
- VRCA 47.66
- 52 Week Low
- BOLD $1.06
- VRCA $0.38
- 52 Week High
- BOLD $12.26
- VRCA $11.41
- Technical
- Relative Strength Index (RSI)
- BOLD N/A
- VRCA 39.53
- Support Level
- BOLD N/A
- VRCA $0.45
- Resistance Level
- BOLD N/A
- VRCA $0.48
- Average True Range (ATR)
- BOLD 0.00
- VRCA 0.04
- MACD
- BOLD 0.00
- VRCA -0.00
- Stochastic Oscillator
- BOLD 0.00
- VRCA 22.13
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.